Login to Your Account

Clinic Roundup

Wednesday, September 18, 2013
• Celtaxsys Inc., of Atlanta, said it completed the first two trials in its Phase I program testing lead candidate CTX-4430, a small-molecule inhibitor of leukotriene A4 hydrolase in development for treating cystic fibrosis (CF) lung disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription